pipobroman has been researched along with Blood Clot in 10 studies
Pipobroman: An antineoplastic agent that acts by alkylation.
pipobroman : An N-acylpiperazine that is piperazine in which each of the nitrogens has been acylated by a 3-bromopropionoyl group. An anti-cancer drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 9.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 6.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 5.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| "From 1968 to 1993, 179 newly diagnosed patients with polycythemia vera (PV) were enrolled in a prospective study using pipobroman as first chemotherapy." | 5.10 | Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. ( Bernard, JF; Bruno, F; Gardin, C; Kiladjian, JJ; Renoux, M, 2003) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "Pipobroman (PB) is a neutral amide of piperazine with a chemical structure close to that of alkylating agents, although the exact mechanism of action of PB has not been demonstrated." | 2.42 | Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. ( Lazzarino, M; Passamonti, F, 2003) |
| "The risk of major thrombosis is higher in ET patients aged more than 60 ys." | 2.39 | Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Acute myeloid leukaemia, myelofibrosis and solid tumours occurred in three, two and seven patients with a 10-year cumulative risk of 3%, 2% and 7% respectively." | 1.31 | Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. ( Astori, C; Baratè, C; Bernasconi, P; Brusamolino, E; Canevari, A; Cazzola, M; Corso, A; Lazzarino, M; Malabarba, L; Orlandi, E; Pascutto, C; Passamonti, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tefferi, A | 2 |
| Barbui, T | 2 |
| Kiladjian, JJ | 2 |
| Gardin, C | 1 |
| Renoux, M | 1 |
| Bruno, F | 1 |
| Bernard, JF | 1 |
| Passamonti, F | 3 |
| Lazzarino, M | 3 |
| Rumi, E | 1 |
| Malabarba, L | 2 |
| Arcaini, L | 1 |
| Orlandi, E | 2 |
| Brusamolino, E | 2 |
| Pascutto, C | 2 |
| Cazzola, M | 2 |
| Finazzi, G | 1 |
| Dupuy, E | 1 |
| Brière, J | 1 |
| Heis, N | 1 |
| Rintelen, C | 1 |
| Gisslinger, B | 1 |
| Knöbl, P | 1 |
| Lechner, K | 1 |
| Gisslinger, H | 1 |
| Silverstein, MN | 1 |
| Astori, C | 1 |
| Baratè, C | 1 |
| Canevari, A | 1 |
| Corso, A | 1 |
| Bernasconi, P | 1 |
| Jamshidi, K | 1 |
| Ansari, A | 1 |
| Windschitl, HE | 1 |
| Swaim, WR | 1 |
| Vallée, G | 1 |
| Boivin, P | 1 |
| Dormont, J | 1 |
| Soulier, JP | 1 |
3 reviews available for pipobroman and Blood Clot
| Article | Year |
|---|---|
Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Topics: Abortion, Spontaneous; Acute Disease; Alkylating Agents; Female; Humans; Leukemia, Myeloid; Middle A | 2003 |
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B | 1996 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
1 trial available for pipobroman and Blood Clot
| Article | Year |
|---|---|
Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Deat | 2003 |
6 other studies available for pipobroman and Blood Clot
| Article | Year |
|---|---|
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
Topics: Adult; Cause of Death; Drug Evaluation; Female; Humans; Incidence; Leukemia; Longitudinal Studies; M | 2004 |
The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Drug Tolerance; Erysipelas; Erythropoiesis; Female; Hemato | 1999 |
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle A | 2002 |
Primary thrombocythemia.
Topics: Adult; Aged; Blood Coagulation Tests; Bone Marrow Examination; Busulfan; Follow-Up Studies; Gastroin | 1973 |
[Present treatment of the Vaquez's disease].
Topics: Aged; Anemia; Anticoagulants; Antineoplastic Agents; Blood Donors; Blood Volume; Bloodletting; Busul | 1969 |